Latest news with #Vascular&ThoracicInstitute
Al Etihad
3 days ago
- Business
- Al Etihad
Cleveland Clinic Abu Dhabi sets new standard in cardiovascular care with AlphaVac procedure
3 June 2025 13:51 ABU DHABI (ALETIHAD)Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully performed the AlphaVac thrombectomy, marking a significant milestone in advanced vascular AlphaVac device is a vacuum-assisted medical tool used to remove dangerous blood clots from the body, particularly large veins in the heart and minimally invasive, catheter-based technique helps reduce the risk of postoperative complications compared to traditional open-heart breakthrough procedure was performed by the hospital's Heart, Vascular & Thoracic Institute (HVTI) on a critically ill 70-year-old patient with multiple severe underlying health conditions, including hypertension, chronic kidney disease, heart failure, and atrial fibrillation (irregular heartbeats).The patient also had coronary artery disease and aortic valve stenosis, which is the narrowing of the heart's blood vessels and main valve, which had previously required her to undergo open-heart Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi, stated, 'As medical advancements rapidly accelerate, building a sustainable healthcare system requires a relentless commitment to innovation. Over the past decade, Cleveland Clinic Abu Dhabi has integrated cutting-edge technologies that improve patient outcomes and transform complex care delivery.'Dr. Houssam Younes, Department Chair, Vascular Surgery, Heart, Vascular & Thoracic Institute at Cleveland Clinic Abu Dhabi, said, "The AlphaVac offers a distinct minimally invasive advantage with its innovative nitinol basket and expandable funnel tip. It allows us to efficiently engage and remove large clot burdens with minimal blood loss."This case highlights the serious risks of lead infections and demonstrates how Cleveland Clinic Abu Dhabi is changing the landscape of high-risk cardiovascular care. Using the latest technology, the team safely removed the clot and the pacemaker, resolving the infection and ultimately helping the patient recover with minimal disruption. Source: Aletihad - Abu Dhabi
Yahoo
09-04-2025
- Health
- Yahoo
New drug cuts down genetically inherited heart disease risk factor
(NewsNation) — An experimental drug has shown success in lowering the risk of genetically inherited heart disease by 94 percent during the second phase of its trial. Lepodisiran, an experimental drug from the pharmaceutical company Eli Lilly, is a small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease, according to a press release Sunday. 'Nearly a quarter of the world's population has elevated levels of Lp(a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,' said Steven Nissen, chief academic officer of the Heart, Vascular & Thoracic Institute at the Cleveland Clinic. 'Unfortunately, there are no approved cholesterol-lowering therapies specifically for this genetic risk factor, and lifestyle changes like diet and exercise do not provide meaningful reductions,' Nissan added. But, he continued, 'these significant and sustained Lp(a) reductions are encouraging and suggest that siRNA approaches like lepodisiran could potentially offer durable benefits with long-term dosing.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
01-04-2025
- Health
- Yahoo
New drug cuts down genetically inherited heart disease risk factor
(NewsNation) — An experimental drug has shown success in lowering the risk of genetically inherited heart disease by 94 percent during the second phase of its trial. Lepodisiran, an experimental drug from the pharmaceutical company Eli Lilly, is a small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease, according to a press release Sunday. 'Nearly a quarter of the world's population has elevated levels of Lp(a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,' said Steven Nissen, chief academic officer of the Heart, Vascular & Thoracic Institute at the Cleveland Clinic. 'Unfortunately, there are no approved cholesterol-lowering therapies specifically for this genetic risk factor, and lifestyle changes like diet and exercise do not provide meaningful reductions,' Nissan added. But, he continued, 'these significant and sustained Lp(a) reductions are encouraging and suggest that siRNA approaches like lepodisiran could potentially offer durable benefits with long-term dosing.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
The Hill
01-04-2025
- Health
- The Hill
New drug cuts down genetically inherited heart disease risk factor
(NewsNation) — An experimental drug has shown success in lowering the risk of genetically inherited heart disease by 94 percent during the second phase of its trial. Lepodisiran, an experimental drug from the pharmaceutical company Eli Lilly, is a small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease, according to a press release Sunday. 'Nearly a quarter of the world's population has elevated levels of Lp(a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,' said Steven Nissen, chief academic officer of the Heart, Vascular & Thoracic Institute at the Cleveland Clinic. 'Unfortunately, there are no approved cholesterol-lowering therapies specifically for this genetic risk factor, and lifestyle changes like diet and exercise do not provide meaningful reductions,' Nissan added. But, he continued, 'these significant and sustained Lp(a) reductions are encouraging and suggest that siRNA approaches like lepodisiran could potentially offer durable benefits with long-term dosing.'
